Join the Neuropathic Pain group to help and get support from people like you.
Neuropathic Pain News
Four in 10 Patients Receiving Chemo Develop Chronic Painful Neuropathy
TUESDAY, Feb. 4, 2025 – The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced peripheral neuropathy (CIPN), according to a meta-analysis...
Chemo Causes Nerve Pain For Many Cancer Patients
WEDNESDAY, Jan. 29, 2025 – Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence review suggests. These patients might experience loss of...
Micronized Amnion/Chorion Aids Interstitial Cystitis/Bladder Pain Syndrome
THURSDAY, Oct. 31, 2024 – Injected micronized amnion/chorion bilayer (AC) product significantly reduces time to symptom relief in patients with refractory interstitial cystitis/bladder pain syndrome...
Are Antidepressants Being Overused to Treat Seniors' Pain?
FRIDAY, Sept. 20, 2024 – Doctors sometimes turn to antidepressants as a means of easing older people's physical pain, but a new expert review finds there's little evidence to support the practice....
Plasma Biomarkers of Alzheimer Neuropathy Linked to Dementia Risk
THURSDAY, Aug. 1, 2024 – Plasma biomarkers of Alzheimer disease (AD) neuropathy increase with age and are associated with known dementia risk factors, according to a study published online July 28...
Exercise May Prevent the Nerve Damage That Comes With Chemotherapy
TUESDAY, July 2, 2024 – Simple exercises performed during rounds of chemotherapy can help people avoid nerve damage normally associated with the cancer-killing drugs, a new study suggests. About...
Averitas Pharma Announces FDA Approval of Qutenza for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet
AACHEN, Germany and MORRISTOWN, N.J., July 21, 2020 /PRNewswire/ – Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval ...
FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions
October 12, 2017 - Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily...
Further information
Related condition support groups
Related drug support groups
gabapentin, Lyrica, amitriptyline, pregabalin, doxepin, oxcarbazepine